The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired - II | Acquired

About Prosarix

Prosarix is a computational chemistry company specializing in small molecule screening and design. Through the use of its technology platform, ProtoDiscovery, the Company carries out serviced-based discovery projects as well as generating pre-clinical development candidates for out-licensing.

Prosarix Headquarter Location

Newton Hall Town Street

Cambridge, England, CB22 7ZE,

United Kingdom

+44 (0)1223 870400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Prosarix News

RxCelerate acquires UK-based molecular modeling company

Feb 7, 2019

By Melissa Fassbender The outsourced drug discovery and development firm has acquired Prosarix, a UK-based molecular modeling company. Now, RxCelerate has announced its acquisition of Prosarix, a molecular modeling company that supports both protein engineering and in silico​ drug design projects. “Following the acquisition of bioanalytical CRO Total Scientific and sector-focused back-office service provider The Cambridge Partnership during 2018, this new acquisition underlines our commitment to complete the jigsaw, so that our clients can access world-leading drug discovery capability under one roof,”​ said RxCelerate Founder and Chairman Dr. David Grainger in a press release. Prosarix’s ProtoDiscovery platform for small molecule design and protein engineering has been in use since the company’s inception in 2006. RxCelerate has not responded to a request for comment. Copyright - Unless otherwise stated all contents of this web site are © 2019 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

  • When was Prosarix founded?

    Prosarix was founded in 2006.

  • Where is Prosarix's headquarters?

    Prosarix's headquarters is located at Newton Hall, Cambridge.

  • What is Prosarix's latest funding round?

    Prosarix's latest funding round is Acquired - II.

  • Who are the investors of Prosarix?

    Investors of Prosarix include RxCelerate and Evolva Holding.

  • Who are Prosarix's competitors?

    Competitors of Prosarix include Oxford Drug Design, CellCentric, MerLion Pharmaceuticals, Nuevolution, Melinta Therapeutics and 16 more.

You May Also Like

Silicos Logo

silicos aims to empower virtual screening for in silico drug discovery

MerLion Pharmaceuticals

MerLion Pharmaceuticals focuses on the discovery and development of drug candidates from natural sources. MerLion collaborates with leading pharmaceutical companies, biotechs and research institutes to identify and develop drug leads in a wide range of therapeutic areas.


VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

Nereus Pharmaceuticals

Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.

AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.


Glycopep is engaged in the synthesis and development of unique chemicals and resin products to support drug discovery. Glycopep is providing custom synthesis to academic institutions and pharmaceutical/biotech companies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.